PATENT CLAIM ANALYSIS

Application Number: 15768025
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["514", "210210"]

Abstract:
The invention relates to novel ferroportin inhibitors of the general formula (I) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.

Claim (Index 18):
Compounds for the use according to any one of the preceding claims, wherein\n wherein Z is an optionally substituted 5- or 6-membered heterocyclic group N-Cycl of the formula (IId)) wherein N-Cycl is a nitrogen containing 5- or 6-membered heterocyclyl group and wherein R 1 , R 2 , R 3 , A 1 , A 2  and Ar have the meaning as defined in the preceding claims, forming compounds according to formula (IId-a) or (IId-b) wherein the heterocyclyl ring may be substituted with 1 to 3 substituents.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 91.0
- Lexical Diversity: 1.25532
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15769148', '14310254', '15517528', '14007533', '15185186']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7883058745389123
- 35 USC 102 Novelty (BERT): 0.5552765381204802
- Combined Prediction Score: 0.7650029408970691
- Mean Citation Score: 298.633386
- Max Citation Score: 422.5474
- Similarity Product: 348.43504634892935

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test